Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
van Ojik
H H
HH
Department of Internal Medicine, University Hospital, Utrecht, The Netherlands.
Repp
R
R
Groenewegen
G
G
Valerius
T
T
van de Winkel
J G
JG
D000328:Adult; D000368:Aged; D018033:Antibodies, Bispecific / Q000097:blood / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology*; D011994:Recombinant Proteins
D018033:Antibodies, Bispecific; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor; D018719:Erb-b2 Receptor Tyrosine Kinases; D017452:Receptors, IgG; D011994:Recombinant Proteins